Axovant to Present at 2019 RBC Capital Markets Global Healthcare Conference
May 20 2019 - 7:00AM
Axovant Gene Therapies Ltd. (Nasdaq: AXGT), a clinical-stage
company developing innovative gene therapies, today announced that
Pavan Cheruvu, M.D., chief executive officer, will present at the
2019 RBC Capital Markets Global Healthcare Conference on May 21,
2019 at 2:05 p.m. (Eastern Time).
A live webcast will be available in the Events
section of Axovant's website at www.axovant.com. A replay will be
available for approximately 30 days following the conference.
About Axovant Gene
Therapies
Axovant, part of the Roivant family of companies, is a
clinical-stage gene therapy company focused on developing a
pipeline of innovative product candidates for debilitating
neurological and neuromuscular diseases. The company’s current
pipeline of gene therapy candidates targets GM1 gangliosidosis, GM2
gangliosidosis (including Tay-Sachs disease and Sandhoff disease),
Parkinson’s disease, oculopharyngeal muscular dystrophy (OPMD),
amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.
Axovant is focused on accelerating product candidates into and
through clinical trials with a team of experts in gene therapy
development and through external partnerships with leading gene
therapy organizations. For more information, visit
www.axovant.com.
About Roivant
Roivant Sciences aims to improve health by rapidly delivering
innovative medicines and technologies to patients. It does this by
building Vants – nimble, entrepreneurial biotech and healthcare
technology companies with a unique approach to sourcing talent,
aligning incentives, and deploying technology to drive greater
efficiency in R&D and commercialization. For more information,
please visit www.roivant.com.
Contacts:
MediaMike BeyerSam Brown Inc.
(312) 961-2502mikebeyer@sambrown.commedia@axovant.com
InvestorsTricia
TruehartAxovant(631) 892-7014investors@axovant.com
Axovant Gene Therapies (NASDAQ:AXGT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Axovant Gene Therapies (NASDAQ:AXGT)
Historical Stock Chart
From Sep 2023 to Sep 2024